OPKO Health Inc (OPK) posted $65.4 million in Q3 2026 revenue and a $722 million LabCorp cash windfall, while widening biotech losses and a delayed CAR-T timeline tempered the outlook.
MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business high...
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
KIRYAT GAT, Israel, Oct. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Biologics Ltd., an OPKO Health company (NASDAQ: OPK), today announced that the first ...
Insiders at American Airlines, Opko Health, Intel, Bed Bath & Beyond, and Align Technology expressed great confidence in their companies. Read more here.
OPKO Health eyes growth from RAYALDEE, partner revenues and a leaner BioReference, while pipeline and reimbursement risks remain key concerns.
Earlier this month, OPKO Health expanded its financing relationship with HealthCare Royalty by issuing US$125 million in senior secured notes backed by future mazdutide royalty payments from China, allowing it to raise capital without issuing new shares and with total repayments capped at 1.5 times the amount received. This royalty-backed financing structure highlights how OPKO Health is using its metabolic therapy partnerships to access non-dilutive funding while preserving potential...
On August 13, OPKO Health (NASDAQ:OPK) expanded its financing relationship with HealthCare Royalty, a business of KKR, issuing an additional $125 million in senior secured notes secured by the royalty stream tied to mazdutide, the GLP-1 drug OPKO licensed to Eli Lilly and now collects royalties on in China. The notes mature in 2044, matching […]
OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
This is the newest page. Registered accounts read further back.